Advicenne

ALDVI

FR0013296746

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:29 2024-05-10 am EDT			5-day change	1st Jan Change
1.794 ^EUR	-0.33%		+8.86%	-32.56%

Apr. 08	Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 25	Advicenne: ODD designation in cystinuria	CF

Advicenne Appoints André Ulmann as Chief Medical Officer

January 07, 2021 at 01:00 am EST

Advicenne announced that Dr. André Ulmann, who has been serving as interim CEO, will assume the position of Chief Medical Officer of the Company.

Latest news about Advicenne

Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 07	CI
Advicenne: ODD designation in cystinuria	Mar. 25	CF
Advicenne: share price hit after 2023 sales figures	Jan. 24	CF
Advicenne: Cemag Invest above 15% threshold	23-10-09	CF
Advicenne: CDC holds less than 25% of votes	23-10-09	CF
Advicenne Kicks Off Share Offering to Achieve Operational Breakeven	23-09-12	MT
Advicenne: launch of a capital increase	23-09-11	CF
Advicenne S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-10	CI
Advicenne: reduced losses for fiscal 2022	23-03-31	CF
Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Advicenne: Sibnayal launched in Denmark	23-03-06	CF
Advicenne Wins Danish Marketing Approval for Distal Renal Tubular Acidosis Treatment Sibnayal	23-03-06	MT
Advicenne Announces the Launch of Sibnayal in Denmark	23-03-06	CI
Global markets live: Adecco, Bayer, Chevron, Target, Tesla...	23-02-28
Advicenne: new distribution agreement signed in Europe	23-02-28	CF
Advicenne Completes European Commercial Coverage of Sibnayal(R) Through Its Agreement with Avanzanite Bioscience	23-02-28	CI
Advicenne: distribution agreement for Southern Europe	23-02-14	CF
Advicenne and SPA Società Prodotti Antibiotici Announce an Exclusive Distribution Agreement for the Marketing of Sibnayal® in Italy, Spain and Portugal	23-02-14	CI
Advicenne Provides an Update on Its Commercial Partnerships in Europe and the Middle East	23-02-01	CI
Advicenne: 13% growth in annual sales	23-01-24	CF
Advicenne S.A. Reports Sales Results for the Year 2022	23-01-24	CI
Advicenne's Distal Renal Tubular Acidosis Drug Receives Orphan Drug Designation in US	22-12-13	MT
Advicenne Announces the Second Tranche Drawdown of its Non-dilutive Financing Agreement With the EIB	22-12-05	CI
Advicenne S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-20	CI
Advicenne Wins Scottish Approval For Distal Renal Tubular Acidosis Drug	22-09-14	MT

Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2023, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Advicenne

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.794 EUR

Average target price

6.9 EUR

Spread / Average Target

+284.62%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ADVICENNE	-32.56%	23.73M
CSL LIMITED	-2.61%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.9B
BIOGEN INC.	-14.40%	32.25B
UCB	+55.89%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.39B
INCYTE CORPORATION	-15.50%	11.91B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	9.03B

Biopharmaceuticals

Advicenne

Equities

ALDVI

FR0013296746

Pharmaceuticals

Advicenne Appoints André Ulmann as Chief Medical Officer

Latest news about Advicenne

Chart Advicenne

Company Profile

Income Statement Evolution

Ratings for Advicenne

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals